KR102513886B1 - Ido1 효소를 영상화하기 위한 방사성리간드 - Google Patents

Ido1 효소를 영상화하기 위한 방사성리간드 Download PDF

Info

Publication number
KR102513886B1
KR102513886B1 KR1020197004720A KR20197004720A KR102513886B1 KR 102513886 B1 KR102513886 B1 KR 102513886B1 KR 1020197004720 A KR1020197004720 A KR 1020197004720A KR 20197004720 A KR20197004720 A KR 20197004720A KR 102513886 B1 KR102513886 B1 KR 102513886B1
Authority
KR
South Korea
Prior art keywords
ido1
compound
radiolabeled compound
imaging
radiolabeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197004720A
Other languages
English (en)
Korean (ko)
Other versions
KR20190030727A (ko
Inventor
데이비드 제이. 도넬리
에린 리 콜
리처드 찰스 버렐
웨슬리 에이. 털리
앨번 제이. 알렌토프
마이클 아서 월리스
제임스 아론 발로그
오드리스 후앙
메테 스킨비에르그
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20190030727A publication Critical patent/KR20190030727A/ko
Application granted granted Critical
Publication of KR102513886B1 publication Critical patent/KR102513886B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
KR1020197004720A 2016-07-19 2017-07-18 Ido1 효소를 영상화하기 위한 방사성리간드 Active KR102513886B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
US62/364,020 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (2)

Publication Number Publication Date
KR20190030727A KR20190030727A (ko) 2019-03-22
KR102513886B1 true KR102513886B1 (ko) 2023-03-27

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004720A Active KR102513886B1 (ko) 2016-07-19 2017-07-18 Ido1 효소를 영상화하기 위한 방사성리간드

Country Status (12)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039518A1 (en) * 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR102669173B1 (ko) * 2017-06-30 2024-05-23 브리스톨-마이어스 스큅 컴퍼니 치환된 퀴놀리닐시클로헥실프로판아미드 화합물 및 그의 개선된 제조 방법
CN111669802A (zh) * 2017-11-21 2020-09-15 Oppo广东移动通信有限公司 传输信息的方法、网络设备和终端设备
EP3720843A1 (en) * 2017-12-05 2020-10-14 GlaxoSmithKline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
ES2557407T3 (es) * 2010-03-01 2016-01-25 Tau Therapeutics Llc Procedimiento de imaginología de una enfermedad

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Also Published As

Publication number Publication date
EP3487516A1 (en) 2019-05-29
US20220305144A1 (en) 2022-09-29
BR112019000499A2 (pt) 2019-04-24
EA201990198A1 (ru) 2019-06-28
JP6987840B2 (ja) 2022-01-05
CA3031079A1 (en) 2018-01-25
IL264187A (en) 2019-02-28
US20190282714A1 (en) 2019-09-19
AU2017298262B2 (en) 2024-07-18
JP2019527225A (ja) 2019-09-26
MX2019000508A (es) 2019-03-28
AU2017298262A1 (en) 2019-03-07
CN109475594A (zh) 2019-03-15
SG11201900336YA (en) 2019-02-27
KR20190030727A (ko) 2019-03-22
EA039877B1 (ru) 2022-03-23
IL264187B (en) 2021-06-30
WO2018017529A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
KR102513886B1 (ko) Ido1 효소를 영상화하기 위한 방사성리간드
TWI589302B (zh) 用於合成造影劑及其中間體之方法及裝置
KR101726471B1 (ko) 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
US20250057995A1 (en) Radioligands for imaging the lpa1 receptor
JP6927974B2 (ja) 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
EP3062827A1 (en) Radioligands for imaging the lpa-1 receptor
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
JP2019507155A (ja) 放射性標識大環状ｅｇｆｒ阻害剤
CA3031079C (en) Radioligands for imaging the ido1 enzyme
US20250340562A1 (en) Chromane imaging ligands
KR100706760B1 (ko) 티로신 유도체 및 그것을 포함하는 약제학적 조성물
WO2025188917A1 (en) Construction and use of reagents for conjugation to bioligands for imaging and radiopharmaceutical applications
JP2024534191A (ja) ブルトン型チロシンキナーゼのｐｅｔ画像化に有用な化合物
WO2022192645A1 (en) Compounds for brain imaging
HK1241356A1 (en) Compositions, methods and systems for the synthesis and use of imaging agents
HK40029571B (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
HK1182933A (en) Compositions, methods and systems for the synthesis and use of imaging agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220217

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220217

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220418

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221220

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221111

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220418

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230321

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230322

End annual number: 3

Start annual number: 1

PG1601 Publication of registration